DOES SARS-COV2 INFECTION CHANGE THE LEVEL OF FIBRINOGEN AT PREGNANCY?

Abbassi-Ghanavati, M., Greer, L. G., & Cunningham, F. G. (2009). Pregnancy and laboratory studies: a reference table for clinicians. Obstetrics & Gynecology, 114(6), 1326-1331.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., . . . Wei, Y. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223), 507-513.

Colling, M. E., & Kanthi, Y. (2020). <? covid19?> COVID–19-associated coagulopathy: An exploration of mechanisms. Vascular Medicine, 25(5), 471-478.

Ditschuneit, H. H., Flechtner-Mors, M., & Adler, G. (1995). Fibrinogen in obesity before and after weight reduction. Obes Res, 3(1), 43-48. doi:10.1002/j.1550-8528.1995.tb00119.x

Greer, I. A., & Nelson-Piercy, C. (2005). Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 106(2), 401-407.

Harenberg, J., & Favaloro, E. (2020). COVID-19: progression of disease and intravascular coagulation–present status and future perspectives. Clinical Chemistry and Laboratory Medicine (CCLM), 58(7), 1029-1036.

Jamieson, D. J., Theiler, R. N., & Rasmussen, S. A. (2006). Emerging infections and pregnancy. Emerging infectious diseases, 12(11), 1638.

Kadir, R. A., Kobayashi, T., Iba, T., Erez, O., Thachil, J., Kazi, S., . . . Othman, M. (2020). COVID‐19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women’s Health. Journal of Thrombosis and Haemostasis, 18(11), 3086-3098.

Kollias, A., Kyriakoulis, K. G., Stergiou, G. S., & Syrigos, K. (2020). Heterogeneity in reporting venous thromboembolic phenotypes in COVID‐19: methodological issues and clinical implications. British journal of haematology, 190(4), 529-532.

Liu, Y.-C., Kuo, R.-L., & Shih, S.-R. (2020). COVID-19: The first documented coronavirus pandemic in history. Biomedical journal, 43(4), 328-333.

Machlus, K. R., Cardenas, J. C., Church, F. C., & Wolberg, A. S. (2011). Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood, The Journal of the American Society of Hematology, 117(18), 4953-4963.

Manten, G. T., Franx, A., Sikkema, J., Hameeteman, T. M., Visser, G. H., de Groot, P. G., & Voorbij, H. A. (2004). Fibrinogen and high molecular weight fibrinogen during and after normal pregnancy. Thrombosis research, 114(1), 19-23.

Sultan, A. A., West, J., Tata, L. J., Fleming, K. M., Nelson‐Piercy, C., & Grainge, M. J. (2012). Risk of first venous thromboembolism in and around pregnancy: a population‐based cohort study. British journal of haematology, 156(3), 366-373.

Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 18(4), 844-847.

Thachil, J., Tang, N., & Gando, S. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID-19. 18(5), 1023-1026. doi:10.1111/jth.14810

Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., . . . Yu, T. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine, 8(5), 475-481.

Zambrano, L. D., Ellington, S., Strid, P., Galang, R. R., Oduyebo, T., Tong, V. T., . . . Gilboa, S. M. (2020). Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. Morbidity and Mortality Weekly Report, 69(44), 1641.